As a result of the successful share offering, we will raise nearly PLN 53 million. These funds will be used, among other things, to build a large-scale stem cell production facility. The new facility will enable us to commercially produce drugs that combat the most common diseases in companion animals. My Company Polska describes the details of the transaction today.
Read more: Bioceltix pozyska prawie 53 mln zł na budowę nowej wytwórni komórek macierzystych
MACHINE TRANSLATION